Header01-REBRAND_MENARINISILICONBIOSYSTEMS

 

Press Releases

05/27/2021

Menarini Silicon Biosystems launches new breakthrough DEPArray™ PLUS image-based cell sorter to isolate rare cells with single cell precision


DEPArray™ PLUS – the new automated and versatile platform to investigate pre-selected rare cell populations from various samples with 100% purity, now enhanced with 9 fluorescent channels and remarkably improved user experience

continue →

Topics: Forensics, CTCs, cell sorting, Oncology, DEPArray PLUS

02/16/2021

Menarini Silicon Biosystems announces launch of CellMag™ product line offering affordable Gold Standard Circulating Tumor Cells capture


CELLMAG – a cost effective, manual and simple approach for the enrichment and staining of extremely rare cells from blood

continue →

Topics: CTCs, CELLSEARCH, Liquid biopsy, Blood Enrichment, CellMag

06/10/2020

New ASCO Studies Offer Evidence for Use of Circulating Tumor Cells as a Prognostic Biomarker for Advanced Prostate and Breast Cancer

Results from prospective trials show a "clear prognostic value" for CTC counts

continue →

Topics: CTCs, CELLSEARCH, metastatic breast cancer, prostate cancer, ASCO

09/23/2019

Menarini Silicon Biosystems to Host ESMO Symposium on Clinical Importance of Circulating Tumor Cells

World-renowned faculty will present current evidence and potential clinical applications of CTCs for advanced breast and prostate cancer

continue →

Topics: CTCs, Liquid biopsy, Precision Medicine, rare cells

11/29/2018

New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium

Research Adds to Growing Evidence of Clinical Utility of CTCs for the management of Metastatic Breast Cancer Patients

continue →

Topics: CTCs, CELLSEARCH, Liquid biopsy, Precision Medicine, metastatic breast cancer

03/12/2018

A robust method to study cancer heterogeneity in liquid biopsy

Copy Number Alteration Profiling of Single Circulating Tumor Cells which May Be used to Predict Response to Therapy

continue →

Topics: CTCs, DEPArray NxT, NGS, CELLSEARCH, Liquid biopsy, Precision Medicine, low-pass, copy number alteration

05/16/2017

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington

continue →

Topics: FFPE, CTCs, Liquid biopsy, International experts, Menarini International Foundation, Precision Medicine, Cancer Heterogeneity, International conference

04/3/2017

Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH® Assets

Liquid Biopsy Test for Circulating Tumor Cells Marks Its First Entry into U.S. Diagnostics Market

continue →

Topics: CTCs, deparray, CELLSEARCH, acquisition, CTC test, Liquid biopsy

12/20/2016

Menarini-Silicon Biosystems to Acquire CELLSEARCH® CTC System

Only FDA-Cleared CTC test to join Company’s Portfolio of Diagnostics

continue →

Topics: CTCs, single-cell isolation, deparray, CELLSEARCH

11/25/2016

DEPArray™ Single-Cell Isolation Technology Enables Researchers to Develop a Model for Predicting Response to Treatment in Patients with Lung Cancer

Genetic Profiles of Circulating Tumor Cells May Predict Drug Resistance and Clinical Outcomes

continue →

Topics: CTCs, lung cancer, deparray, SCLC